BIZARRE: 5 - What They Never Told You

Revealed: drug firms funding UK patient groups that lobby for NHS approval of medicines

Observer investigation shows that majority of Nice drug appraisals involve groups financially linked to maker of pharmaceuticals

The Guardian - UK · Jul 22, 2023

Panadol maker plans sweeping job cuts a year after being spun off from GSK

Exclusive: Consumer healthcare firm Haleon to cut hundreds of roles in UK and potentially thousands globally

The Guardian - UK · Jul 13, 2023

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

The Guardian - UK · Jul 8, 2023

Over dinner in Davos, the CEOs of Novartis, Coca-Cola, and Grab shared what’s worrying them

Highlights from Fortune's dinner in Davos.

Fortune · Feb 1, 2023

Coca-Cola and Novartis's CEOs don't care if 'ESG' has become a toxic phrase among some

It's about delivering on corporate missions in a sustainable way, they said at Davos.

Fortune · Jan 23, 2023

1 Large-Cap Stock You Should Purchase This Week

Pharmaceutical company Novartis (NVS) maintained its growth momentum in the third quarter of fiscal 2022, and the company’s growth prospects look promising, supported by its clear focus on five core therapeutic areas, having multiple significant in-market and pipeline assets. Given NVS’ reliable dividend payments and high profitability, this large-cap stock…

StockNews.com · Jan 13, 2023

I can’t get my HRT, again – this second UK shortage wasn’t supposed to happen

The government claims that supply issues have been tackled, but menopausal women know this is far from the truth, says author Rose George

The Guardian - UK · Dec 7, 2022

Pharma's expensive gaming of the drug patent system is successfully countered by the Medicines Patent Pool, which increases global access and rewards innovation

Biomedical innovation reached a new era during the COVID-19 pandemic as drug development went into overdrive. But the ways that brand companies license their patented drugs grant them market monopoly, preventing other entities from making generics so they can exclusively profit. This significantly limits the reach of lifesaving drugs, especially…

The Conversation · Dec 5, 2022

Gene drug ‘only hope’ for Turkish child, but costs millions

Zolgensma may stop five-year-old Yusuf Polat’s spinal muscular atrophy from progressing, but it costs $2.1m.

Al Jazeera · Nov 21, 2022

Queensland researchers find immune-boosting drug could lessen COVID-19 severity if antivirals fade

Unlike antiviral treatments, researchers say the experimental medication would not attack the virus that causes COVID-19, but target the immune system instead.

ABC News · Nov 17, 2022